Ithaca, NY Company, Bionexus, Introduces First Natural Skin Care Lotion for Dogs Containing Standardized Nigella sativa Extracts
Bionexus® launches DogsBestFriend™, an all natural, lotion for hot spots, insect bites, allergies, calluses, and itchy or dry skin, formulated with the first supercritical fluid extract of Nigella sativa and standardized thymoquinone content.
Ithaca, NY April 17, 2012 – Dr. Linda M. Pacioretty, Bionexus CEO, today announced the national market launch of the Company’s first canine product, DogsBestFriend™. This innovative, all natural, skin-care lotion for dogs combines one of the oldest traditional medicines, Nigella sativa seed oils, with the newest extraction technology, supercritical fluid extraction. The result is a breakthrough, natural replacement for hydrocortisone, antihistamines and topical antibiotics powerful enough to help combat dermal inflammation, itching, bacterial and fungal infections and pain, yet safe enough to use on dogs of all ages.
Bionexus’ patent-pending, GellX™ extraction technology and proprietary combination process, produces a healing, moisturizing lotion that contains a unique, hypoallergenic, antimicrobial, and anti-inflammatory combination of omega-3 and omega-6 fatty acids, thymoquinone, retinoids, and mixed tocopherols without the use of toxic chemicals.
“DogsBestFriend is the result of seven years of laboratory studies with thymoquinone and N. sativa extracts,” added Dr. John G. Babish, Bionexus’ Chairman and Chief Science Officer.
Bionexus became interested in N. sativa while characterizing the anti-inflammatory activity of thymoquinone in several cell-culture systems. In the laboratory, however, commercial sources of N. sativa oil did not reproduce the anti-inflammatory effects of thymoquinone. This inconsistency led to a five-year search for an extraction process that would produce reliably potent, anti-inflammatory extracts from N. sativa seeds. Bionexus’ GellX™ patent-pending, nontoxic extraction and recombination technology represents the cumulative efforts of this work.
The national launch of DogsBestFriend follows four-months of test marketing in the northeast. Describing this period, Dr. Pacioretty noted, “Our early clinical testing suggested hot-spot remission could be seen in as little as one day. While this result seemed too good to be expected commercially, our test market customers also noticed the surprisingly rapid relief offered by DogsBestFriend was unlike any product they had previously used.” Typical customer comments regarding hot spots included, “…after only two applications, the hot spot was completely dried up,” and “My dog has never had a hot spot that she didn’t need oral antibiotics to clear up … THRILLED with this product.”
Dog owners also praised DogsBestFriend’s anti-itch and moisturizing qualities: “I put it on my girl who had scratched herself raw and it soothed her skin. In a few days her skin was healed up. We love this product.”
Contact Bionexus’ pet marketing division Brookton Labs at www.brooktonlabs.com for purchasing information and LIKE us on Facebook (www.facebook.com/DogsBestFriendLotion).
Bionexus® Ltd. utilizes a product development model similar to that of the pharmaceutical industry, with a focus on natural ingredients and commercial products for eczema, osteoarthritis, obesity and type 2 diabetes in humans and pets.